The site of the Media Sphera Publishers contains materials intended solely for healthcare professionals.
By closing this message, you confirm that you are a certified medical professional or a student of a medical educational institution.

Login
EN
+7 (495) 482-4118
+7 (495) 482-0604
+8 800 101-59-87
  • (toll-free number for subscriptions)
    Mon-Fri from 10 a.m. to 6 p.m.

  • © 1998-2025
+7 (495) 482-43-29
EN
All journals
Journal
Year
Year
Search result: 0

Alekberzade A.V.

Kafedra khirurgii Pervogo moskovskogo gosudarstvennogo meditsinskogo universiteta im. I.M. Sechenova

Krylov N.N.

Klinika fakul'tetskoĭ khirurgii #1 lechebnogo fakul'teta Pervogo Moskovskogo gosudarstvennogo meditsinskogo universiteta im. I.M. Sechenova

Lipnitskiĭ E.M.

Kafedra khirurgii Pervogo moskovskogo gosudarstvennogo meditsinskogo universiteta im. I.M. Sechenova

Shakhbazov R.O.

Upstate Medical University, Syracuse, NY, USA

Azari F.

Department of Surgery, Hospital of the University of Pennsylvania, Philadelphia PA, USA

Gastric neuroendocrine tumors

Authors:

Alekberzade A.V., Krylov N.N., Lipnitskiĭ E.M., Shakhbazov R.O., Azari F.

More about the authors

Journal: Pirogov Russian Journal of Surgery. 2019;(12): 111‑120

DOI: 10.17116/hirurgia2019121111

Views: 33689

Downloaded: 893

Download PDF (RU)
Contact the author
Table of contents

To cite this article:

Alekberzade AV, Krylov NN, Lipnitskiĭ EM, Shakhbazov RO, Azari F. Gastric neuroendocrine tumors. Pirogov Russian Journal of Surgery. 2019;(12):111‑120. (In Russ.)
https://doi.org/10.17116/hirurgia2019121111

Подписка 2025 (Pirogov Russian Journal of Surgery)
МСФ на ЯМ
Close metadata
Recommended articles:
Surgery for mediastinal tera­toma containing pancreatic tissue. Piro­gov Russian Journal of Surgery. 2024;(2):75-83
The use of Mexi­dol in patients with mild (moderate) cognitive impairment: resu­lts of a meta-analysis. S.S. Korsakov Journal of Neurology and Psychiatry. 2024;(1):82-88
Serum neurofilament light chains in asse­ssing the course of multiple scle­rosis. S.S. Korsakov Journal of Neurology and Psychiatry. 2024;(1):89-93
Plasma and sali­vary acetylcholinesterase acti­vity in amyotrophic late­ral scle­rosis. S.S. Korsakov Journal of Neurology and Psychiatry. 2024;(1):128-134
Diagnostics of HIV-infection in the Chechen Repu­blic: current state and prospects. Russian Journal of Preventive Medi­cine. 2024;(1):17-24
Analytical review of respiratory infe­ctions role in patients with chro­nic obstructive pulmonary disease and asthma. Part 1. Characteristics of respiratory infe­ctions and their long-term consequences. Russian Journal of Preventive Medi­cine. 2024;(1):90-96
Reflexology in patient reha­bilitation with postoperative pain. (Literature review). Problems of Balneology, Physiotherapy and Exercise Therapy. 2023;(6):103-106
Endo­bronchial hama­rtoma. P.A. Herzen Journal of Onco­logy. 2024;(1):59-62
Labo­ratory diagnosis of «key» sexually transmitted infe­ctions. Part II. Russian Journal of Clinical Dermatology and Vene­reology. 2024;(1):6-11
Labo­ratory diagnosis of neurosyphilis: opti­mization ways. Part II. Current approaches and biomarkers. Russian Journal of Clinical Dermatology and Vene­reology. 2024;(1):28-36

Gastrointestinal neuroendocrine tumors are rare neoplasms. Currently, incidence of gastric neuroendocrine tumors (gNETs) is being significantly increased. There are 3 groups of gNETs: types I, II and III. Each type has important features regarding clinical picture, prognosis and treatment strategy. Type I is the most common (70—80%) and associated with chronic atrophic gastritis including autoimmune gastritis and Helicobacter associated atrophic gastritis. Type II (5—6%) is associated with multiple endocrine neoplasia type I and Zollinger—Ellison syndrome (MEN I — ZES). Both types are characterized by hypergastrinemia and small tumor dimension. These neoplasms are multiple and mostly benign. On the contrary, NETs type III (10—15%) is not associated with hypergastrinemia and represented by single large neoplasms. Tumors are malignant as a rule. Therefore, surgical resection and chemotherapy are preferred for these tumors. Endoscopic surgery followed by observation is acceptable for almost all NETS type I and II. At the same time, this approach is advisable only for small and highly differentiated neoplasms type III.

Keywords:

gastric neuroendocrine tumors
pathogenesis
classification
diagnosis
treatment
prognosis

Authors:

Alekberzade A.V.

Kafedra khirurgii Pervogo moskovskogo gosudarstvennogo meditsinskogo universiteta im. I.M. Sechenova

Krylov N.N.

Klinika fakul'tetskoĭ khirurgii #1 lechebnogo fakul'teta Pervogo Moskovskogo gosudarstvennogo meditsinskogo universiteta im. I.M. Sechenova

Lipnitskiĭ E.M.

Kafedra khirurgii Pervogo moskovskogo gosudarstvennogo meditsinskogo universiteta im. I.M. Sechenova

Shakhbazov R.O.

Upstate Medical University, Syracuse, NY, USA

Azari F.

Department of Surgery, Hospital of the University of Pennsylvania, Philadelphia PA, USA

List of references:

  1. Lawrence B, Gustafsson BI, Chan A, Svejda B, Kidd M, Modlin IM. The epidemiology of gastroenteropancreatic neuroendocrine tumors. Endocrinol Metab Clin North Am. 2011;40:1-18. PMID: 21349409 https://doi.org/10.1016/j.ecl.2010.12.005
  2. Rindi G, Klöppel G, Alhman H, Caplin M, Couvelard A, de Herder WW, Erikssson B, Falchetti A, Falconi M, Komminoth P, Körner M, Lopes JM, McNicol AM, Nilsson O, Perren A, Scarpa A, Scoazec JY, Wiedenmann B. TNM staging of foregut (neuro)endocrine tumors: a consensus proposal including a grading system. Virchows Arch. 2006;449:395-401. PMID: 16967267 https://doi.org/10.1007/s00428-006-0250-1
  3. Rindi G, Arnold R, Bosman FT, Capella C, Klimstra DS, Klöppel G, Komminoth P, Solcia E. Nomenctlature and classification of neuroendocrine neoplasms of the digestive system. In: Bosman FT, Carneiro F, Hruban RH, Theise ND, editors. WHO classification of Tumours of the digestive system. Lyon: IARC, 2010;13-14.
  4. Caldarella A, Crocetti E, Paci E. Distribution, incidence, and prognosis in neuroendocrine tumors: a population based study from a cancer registry. Pathol Oncol Res. 2011;17:759-763. PMID: 21476126 https://doi.org/10.1007/s12253-011-9382-y
  5. Cho MY, Kim JM, Sohn JH, Kim MJ, Kim KM, Kim WH, Kim H, Kook MC, Park do Y, Lee JH, Chang H, Jung ES, Kim HK, Jin SY, Choi JH, Gu MJ, Kim S, Kang MS, Cho CH, Park MI, Kang YK, Kim YW, Yoon SO, Bae HI, Joo M, Moon WS, Kang DY, Chang SJ. Current Trends of the Incidence and Pathological Diagnosis of Gastroenteropancreatic Neuroendocrine Tumors (GEP-NETs) in Korea 2000—2009: Multicenter Study. Cancer Res Treat. 2012;44:157-165. PMID: 23091441 https://doi.org/10.4143/crt.2012.44.3.157
  6. Ellis L, Shale MJ, Coleman MP. Carcinoid tumors of the gastrointestinal tract: trends in incidence in England since 1971. Am J Gastroenterol. 2010;105:2563-2569. PMID: 20823835 https://doi.org/10.1038/ajg.2010.341
  7. Ito T, Sasano H, Tanaka M, Osamura RY, Sasaki I, Kimura W, Takano K, Obara T, Ishibashi M, Nakao K, Doi R, Shimatsu A, Nishida T, Komoto I, Hirata Y, Nakamura K, Igarashi H, Jensen RT, Wiedenmann B, Imamura M. Epidemiological study of gastroenteropancreatic neuroendocrine tumors in Japan. J Gastroenterol. 2010;45:234-243. PMID: 20058030 https://doi.org/10.1007/s00535-009-0194-8
  8. Modlin IM, Lye KD, Kidd M. A 50-year analysis of 562 gastric carcinoids: small tumor or larger problem? Am J Gastroenterol. 2004;99:23-32. PMID: 14687136 https://doi.org/10.1046/j.1572-0241.2003.04027.x
  9. Niederle MB, Hackl M, Kaserer K, Niederle B. Gastroenteropancreatic neuroendocrine tumours: the current incidence and staging based on the WHO and European Neuroendocrine Tumour Society classification: an analysis based on prospectively collected parameters. Endocr Relat Cancer. 2010;17:909-918. PMID: 20702725 https://doi.org/10.1677/ERC-10-0152
  10. Hodgson N, Koniaris L, Livingstone A, Franceschi D. Gastric carcinoids: a temporal increase with proton pump introduction. Surg Endosc. 2005;19:1610-1612.
  11. Yao JC, Hassan M, Phan A, Dagohoy C, Leary C, Mares JE, Abdalla EK, Fleming JB, Vauthey JN, Rashid A, Evans DB. One hundred years after «carcinoid»: epidemiology of and prognostic factors for neuroendocrine tumors in 35,825 cases in the United States. J Clin Oncol. 2008;26:3063-3072. PMID: 18565894 https://doi.org/10.1200/JCO.2007.15.4377
  12. Ito T, Igarashi H, Nakamura K, Sasano H, Okusaka T, Takano K, Komoto I, Tanaka M, Imamura M, Jensen RT, Takayanagi R, Shimatsu A. Epidemiological trends of pancreatic and gastrointestinal neuroendocrine tumors in Japan: a nationwide survey analysis. J Gastroenterol. 2015;50:58-64. PMID: 24499825 https://doi.org/10.1007/s00535-014-0934-2
  13. Ono M, Sato H, Kazumori H, Yuki M, Rumi MAK, Ortega-Cava CF, Ishihara Y, Ishihara S, Adachi K, Kinoshita Y. Effect of a gastrin/ cholecystokinin B receptor antagonist, S-0509, on the omeprazole-induced proliferation of gastric mucosa in rats. J Lab Clin Med. 2003;142:364-371.
  14. Rindi G, Luinetti O, Cornaggia M, Capella C, Solcia E. Three subtypes of gastric argyrophil carcinoid and the gastric neuroendocrine carcinoma: a clinicopathologic study. Gastroenterology. 1993;104:994-1006. PMID: 7681798 https://doi.org/10.1016/0016-5085(93)90266-F
  15. Gladdy RA, Strong VE, Coit D, Allen PJ, Gerdes H, Shia J, Klimstra DS, Brennan MF, Tang LH. Defining surgical indications for type I gastric carcinoid tumor. Ann Surg Oncol. 2009;16:3154-3160. PMID: 19727959 https://doi.org/10.1245/s10434-009-0687-y
  16. Dakin GF, Warner RR, Pomp A, Salky B, Inabnet WB. Presentation, treatment, and outcome of type 1 gastric carcinoid tumors. J Surg Oncol. 2006;93:368-372. PMID: 16550587 https://doi.org/10.1002/jso.20468
  17. Kaltsas G, Grozinsky-Glasberg S, Alexandraki KI, Thomas D, Tsolakis AV, Gross D, Grossman AB. Current concepts in the diagnosis and management of type 1 gastric neuroendocrine neoplasms. Clin Endocrinol (Oxf). 2014;81:157-168. PMID: 24750249 https://doi.org/10.1111/cen.12476
  18. Li TT, Qiu F, Qian ZR, Wan J, Qi XK, Wu BY. Classification, clinicopathologic features and treatment of gastric neuroendocrine tumors. World J Gastroenterol. 2014;20:118-125. PMID: 24415864 https://doi.org/10.3748/wjg.v20.i1.118
  19. Massironi S, Sciola V, Spampatti MP, Peracchi M, Conte D. Gastric carcinoids: between underestimation and overtreatment. World J Gastroenterol. 2009;15:2177-2183. PMID: 19437556 https://doi.org/10.3748/wjg.15.2177
  20. Nikou GC, Angelopoulos TP. Current concepts on gastric carcinoid tumors. Gastroenterol Res Pract. 2012;2012:287825. PMID: 23316222 https://doi.org/10.1155/2012/287825
  21. O’Toole D, Delle Fave G, Jensen RT. Gastric and duodenal neuroendocrine tumours. Best Pract Res Clin Gastroenterol. 2012;26:719-735. PMID: 23582915 https://doi.org/10.1016/j.bpg.2013.01.002
  22. Sato Y, Imamura H, Kaizaki Y, Koizumi W, Ishido K, Kurahara K, Suzuki H, Fujisaki J, Hirakawa K, Hosokawa O, Ito M, Kaminishi M, Furuta T, Chiba T, Haruma K. Management and clinical outcomes of type I gastric carcinoid patients: retrospective, multicenter study in Japan. Dig Endosc. 2014;26:377-384. PMID: 24188531 https://doi.org/10.1111/den.12197
  23. Sato Y, Iwafuchi M, Ueki J, Yoshimura A, Mochizuki T, Motoyama H, Sugimura K, Honma T, Narisawa R, Ichida T, Asakura H, Van Thiel DH. Gastric carcinoid tumors without autoimmune gastritis in Japan: a relationship with Helicobacter pylori infection. Dig Dis Sci. 2002;47:579-585. PMID: 11911346
  24. Sato Y. Endoscopic diagnosis and management of type I neuroendocrine tumors. World J Gastrointest Endosc. 2015;7:346-353. PMID: 25901213 https://doi.org/10.4253/wjge.v7.i4.346
  25. cherübl H, Cadiot G, Jensen RT, Rösch T, Stölzel U, Klöppel G. Neuroendocrine tumors of the stomach (gastric carcinoids) are on the rise: small tumors, small problems? Endoscopy. 2010;42:664-671. PMID: 20669078. https://doi.org/10.1055/s-0030-1255564
  26. Zhang L, Ozao J, Warner R, Divino C. Review of the pathogenesis, diagnosis, and management of type I gastric carcinoid tumor. World J Surg. 2011;35:1879-1886. PMID: 21559999 https://doi.org/10.1007/s00268-011-1137-0
  27. Modlin IM, Moss SF, Oberg K, Padbury R, Hicks RJ, Gustafsson BI, Wright NA, Kidd M. Gastrointestinal neuroendocrine (carcinoid) tumours: current diagnosis and management. Med J Aust. 2010;193:46-52.
  28. Pritchard DM, Berry D, Przemeck SM, Campbell F, Edwards SW, Varro A. Gastrin increases mcl-1 expression in type I gastric carcinoid tumors and a gastric epithelial cell line that expresses the CCK-2 receptor. Am J Physiol Gastrointest Liver Physiol. 2008;295:798-805.
  29. Kagawa J, Honda S, Kodama M, Sato R, Murakami K, Fujioka T. Enterocromaffin-like cell tumor induced by Helicobacter pylori infection in Mongolian gerbils. Helicobacter. 2002;7:390-397.
  30. Kidd M, Modlin IM, Eick GN, Camp RL, Mane SM: Role of CCN2/CTGF in the proliferation of Mastomys enterochromaffin-like cells and gastric carcinoid development. Am J Physiol Gastrointest Liver Physiol. 2007;292:191-200.
  31. Schaffer K, McBride EW, Beinborn M, Kopini AS. Interspecies polymorphisms confer constitutive activity to the Mastomys cholecystokinin-B/gastrin receptor. J Biol Chem. 1998;273:28779-28784.
  32. La Rosa S, Inzani F, Vanoli A, Klersy C, Dainese L, Rindi G, Capella C, Bordi C, Solcia E. Histologic characterization and improved prognostic evaluation of 209 gastric neuroendocrine neoplasms. Hum Pathol. 2011;42:1373-1384. PMID: 21531442 https://doi.org/10.1016/j.humpath.2011.01.018
  33. Vanoli A, La Rosa S, Luinetti O, Klersy C, Manca R, Alvisi C, Rossi S, Trespi E, Zangrandi A, Sessa F, Capella C, Solcia E. Histologic changes in type A chronic atrophic gastritis indicating increased risk of neuroendocrine tumor development: the predictive role of dysplastic and severely hyperplastic enterochromaffin-like cell lesions. Hum Pathol. 2013;44:1827-1837. PMID: 23642738 https://doi.org/10.1016/j.humpath.2013.02.005
  34. Borch K, Ahren B, Ahlman H, Falkmer S, Granerus G, Grimelius L. Gastric carcinoids: biologic behavior and prognosis after differentiated treatment in relation to type. Ann Surg. 2005;242:64-73.
  35. Gladdy RA, Strong VE, Coit D, Allen PJ, Gerdes H, Shia J, Klimstra DS, Brennan MF, Tang LH. Defining surgical indications for type I gastric carcinoid tumor. Ann Surg Oncol. 2009;16:3154-3160. PMID: 19727959 https://doi.org/10.1245/s10434-009-0687-y
  36. Jordan PH Jr, Barroso A, Sweeney J. Gastric carcinoids in patients with hypergastrinemia. J Am Coll Surg. 2004;199:552-555.
  37. Modlin IM, Lye KD, Kidd M. Carcinoid tumors of the stomach. Surg Oncol. 2003;12:153-172.
  38. Kidd M, Modlin IM, Mane SM, Camp RL, Eick GN, Latich I, Zikusoka MN. Utility of molecular genetic signatures in the delineation of gastric neoplasia. Cancer. 2006;106:1480-1488.
  39. Safatle-Ribeiro AV, Ribeiro UJr, Corbett CE, Iriya K, Kobata CH, Sakai P, Yagi OK, Pinto PEJr, Zilberstein B, Gama-Rodrigues J. Prognostic value of immunohistochemistry in gastric neuroendocrine (carcinoid) tumors. Eur J Gastroenterol Hepatol. 2007;19:21-28.
  40. Meko JB, Norton JA. Management of patients with Zollinger Ellison syndrome. Ann Rev Med. 1995;46:395-411. PMID: 7598474
  41. Nikou GC, Toubanakis C, Nikolaou P, Giannatou E, Marinou K, Safioleas M, Karamanolis D. Gastrinomas associated with MEN-1 syndrome: new insights for the diagnosis and management in a series of 11 patients. Hepatogastroenterology. 2005;52:1668-1676. PMID: 16334754
  42. Kidd M, Modlin IM, Mane SM, Camp RL, Shapiro MD. Q RT-PCR detection of chromogranin A: a new standard in the identification of neuroendocrine tumor disease. Ann Surg. 2006;243:273-280.
  43. Crosby DA, Donohoe CL, Fitzgerald L, Muldoon C, Hayes B, O’ Toole D, Reynolds JV. Gastric neuroendocrine tumours. Dig Surg. 2012;29:331-348. PMID: 23075625 https://doi.org/10.1159/000342988
  44. Singh R, Yao K, Anagnostopoulos G, Kaye P, Ragunath K. Microcarcinoid tumor diagnosed with high-resolution magnification endoscopy and narrow band imaging. Endoscopy. 2008;40(2):E12. PMID: 18278715 https://doi.org/10.1055/s-2007-995393
  45. Makhlouf HR, Burke AP, Sobin LH. Carcinoid tumors of the ampulla of Vater: a comparison with duodenal carcinoid tumors. Cancer. 1999;85:1241-1249. PMID: 10189128 https://doi.org/10.1002/(SI CI)1097-0142(19990315)85:6<1241::AID-CNCR5>3.0.CO;2-4
  46. Bushnell DL, Baum RP. Standard imaging techniques for neuroendocrine tumors. Endocrinol Metab Clin North Am. 2011;40:153-162. PMID: 21349416 https://doi.org/10.1016/j.ecl.2010.12.002
  47. Burke AP, Sobin LH, Federspiel BH, Shekitka KM, Helwig EB. Carcinoid tumors of the duodenum. A clinicopathologic study of 99 cases. Arch Pathol Lab Med. 1990;114:700-704. PMID: 1694655
  48. Johnbeck CB, Knigge U, Kjær A. PET tracers for somatostatin receptor imaging of neuroendocrine tumors: current status and review of the literature. Future Oncol. 2014;10:2259-2277. PMID: 25471038 https://doi.org/ 10.2217/fon.14.139
  49. Kjaer A, Knigge U. Use of radioactive substances in diagnosis and treatment of neuroendocrine tumors. Scand J Gastroenterol. 2015;50:740-747. PMID: 25959100 https://doi.org/10.3109/00365521.2015.1033454
  50. Kocha W, Maroun J, Kennecke H, Law C, Metrakos P, Ouellet JF, Reid R, Rowsell C, Shah A, Singh S, Van Uum S, Wong R. Consensus recommendations for the diagnosis and management of well-differentiated gastroenterohepatic neuroendocrine tumours: a revised statement from a Canadian National Expert Group. Curr Oncol. 2010;17:49-64.
  51. Bajetta E, Ferrari L, Martinetti A, Celio L, Procopio G, Artale S, Zilembo N, Di Bartolomeo M, Seregni E, Bombardieri E: Chromogranin A, neuron-specific enolase, carcino- embryonic antigen, and hydroxyindole acetic acid evaluation in patients with neuroendocrine tumors. Cancer. 1999;86:858-865. https://doi.org/10.1002/(SICI)1097-0142(19990901)86:5<858::AID-CNCR23>3.0.CO;2-8
  52. Rorstad O. Prognostic indicators for carcinoid neuroendocrine tumors of the gastrointestinal tract. J Surg Oncol. 2005;89:151-160.
  53. Bashir S, Gibril F, Ojeaburu JV, Asgharian B, Entsuah LK, Ferraro G, Crafa P, Bordi C, Jensen RT. Prospective study of the ability of histamine, serotonin or serum chromogranin A levels to identify gastric carcinoids in patients with gastrinomas. Aliment Pharmacol Ther. 2002;16:1367-1382.
  54. Nehar D, Lombard-Bohas C, Olivieri S, Claustrat B, Chayvialle JA, Penes MC, Sas-solas G, Borson-Chazot F. Interest of chromogranin A for diagnosis and follow-up of endocrine tumours. Clin Endocrinol. 2004;60:644-652.
  55. Modlin IM, Latich I, Kidd M, Zikusoka M, Eick G. Therapeutic options for gastrointestinal carcinoids. Clin Gastroenterol Hepatol. 2006;4:526-547.
  56. Guillem P. Gastric carcinoid tumours. Is there a place for antrectomy? Ann Chir. 2005;130:323-326.
  57. Kulke MH, Shah MH, Benson AB, Bergsland E, Berlin JD, Blaszkowsky LS, Emerson L, Engstrom PF, Fanta P, Giordano T, Goldner WS, Halfdanarson TR, Heslin MJ, Kandeel F, Kunz PL, Kuvshinoff BW, Lieu C, Moley JF, Munene G, Pillarisetty VG, Saltz L, Sosa JA, Strosberg JR, Vauthey JN, Wolfgang C, Yao JC, Burns J, Freedman-Cass D. Neuroendocrine tumors, version 1.2015. J Natl Compr Canc Netw. 2015;13:78-108. PMID: 25583772
  58. Kim HH, Kim GH, Kim JH, Choi MG, Song GA, Kim SE. The efficacy of endoscopic submucosal dissection of type I gastric carcinoid tumors compared with conventional endoscopic mucosal resection. Gastroenterol Res Pract. 2014;2014:253860. PMID: 24693280 https://doi.org/10.1155/2014/253860
  59. Sato Y, Takeuchi M, Hashimoto S, Mizuno K, Kobayashi M, Iwafuchi M, Narisawa R, Aoyagi Y. Usefulness of endoscopic submucosal dissection for type I gastric carcinoid tumors compared with endoscopic mucosal resection. Hepatogastroenterology. 2013;60:1524-1529. https://doi.org/10.5754/hge121185
  60. Campana D, Ravizza D, Ferolla P, Faggiano A, Grimaldi F, Albertelli M, Berretti D, Castellani D, Cacciari G, Fazio N, Colao A, Ferone D, Tomassetti P. Clinical management of patients with gastric neuroendocrine neoplasms associated with chronic atrophic gastritis: a retrospective, multicentre study. Endocrine. 2016;51:131-139. PMID: 25814125 https://doi.org/10.1007/s12020-015-0584-z
  61. Ravizza D, Fiori G, Trovato C, Fazio N, Bonomo G, Luca F, Bodei L, Pelosi G, Tamayo D, Crosta C. Long-term endoscopic and clinical follow-up of untreated type 1 gastric neuroendocrine tumours. Dig Liver Dis. 2007;39:537-543. PMID: 17433795 https://doi.org/10.1016/j.dld.2007.01.018
  62. Jann H, Roll S, Couvelard A, Hentic O, Pavel M, MüllerNordhorn J, Koch M, Röcken C, Rindi G, Ruszniewski P, Wiedenmann B, Pape UF. Neuroendocrine tumors of midgut and hindgut origin: tumor-node-metastasis classification determines clinical outcome. Cancer. 2011;117:3332-3341. PMID: 21246527 https://doi.org/10.1002/cncr.25855
  63. Jenny HE, Ogando PA, Fujitani K, Warner RR, Divino CM. Laparoscopic antrectomy: a safe and definitive treatment in managing type 1 gastric carcinoids. Am J Surg. 2016;211:778-782. PMID: 26992358 https://doi.org/10.1016/j.amjsurg.2015.08.040
  64. Ozao-Choy J, Buch K, Strauchen JA, Warner RR, Divino CM. Laparoscopic antrectomy for the treatment of type I gastric carcinoid tumors. J Surg Res. 2010;162:22-25. PMID: 20421108 https://doi.org/10.1016/j.jss.2010.01.005
  65. Campana D, Nori F, Pezzilli R, Piscitelli L, Santini D, Brocchi E, Corinaldesi R, Tomassetti P. Gastric endocrine tumors type I: treatment with long-acting somatostatin analogs. Endocr Relat Cancer. 2008;15:337-342. PMID: 18310299 https://doi.org/10.1677/ERC-07-0251
  66. Grozinsky-Glasberg S, Kaltsas G, Gur C, Gal E, Thomas D, Fichman S, Alexandraki K, Barak D, Glaser B, Shimon I, Gross DJ. Long-acting somatostatin analogues are an effective treatment for type 1 gastric carcinoid tumours. Eur J Endocrinol. 2008;159:475-482. PMID: 18662970 https://doi.org/10.1530/EJE-08-0420
  67. Manfredi S, Pagenault M, de Lajarte-Thirouard AS, Bretagne JF. Type 1 and 2 gastric carcinoid tumors: long-term follow-up of the efficacy of treatment with a slow-release somatostatin analogue. Eur J Gastroenterol Hepatol. 2007;19:1021-1025. PMID: 18049175 https://doi.org/10.1097/MEG.0b013e328220eae0
  68. Thomas D, Tsolakis AV, Grozinsky-Glasberg S, Fraenkel M, Alexandraki K, Sougioultzis S, Gross DJ, Kaltsas G. Long-term follow-up of a large series of patients with type 1 gastric carcinoid tumors: data from a multicenter study. Eur J Endocrinol. 2013;168:185-193. PMID: 23132699 https://doi.org/10.1530/EJE-12-0836
  69. Jianu CS, Fossmark R, Syversen U, Hauso Ø, Fykse V, Waldum HL. Five-year follow-up of patients treated for 1 year with octreotide long-acting release for enterochromaffin-like cell carcinoids. Scand J Gastroenterol. 2011;46:456-463. PMID: 21133821 https://doi.org/10.3109/00365521.2010.539255
  70. Massironi S, Zilli A, Conte D. Somatostatin analogs for gastric carcinoids: For many, but not all. World J Gastroenterol. 2015;21:6785-6793. PMID: 26078554 https://doi.org/10.3748/wjg.v21.i22.6785
  71. Massironi S, Zilli A, Fanetti I, Ciafardini C, Conte D, Peracchi M. Intermittent treatment of recurrent type-1 gastric carcinoids with somatostatin analogues in patients with chronic autoimmune atrophic gastritis. Dig Liver Dis. 2015;47:978-983. PMID: 26321479 https://doi.org/10.1016/j.dld.2015.07.155
  72. Fossmark R, Sørdal Ø, Jianu CS, Qvigstad G, Nordrum IS, Boyce M, Waldum HL. Treatment of gastric carcinoids type 1 with the gastrin receptor antagonist netazepide (YF476) results in regression of tumours and normalisation of serum chromogranin A. Aliment Pharmacol Ther. 2012;36:1067-1075. PMID: 23072686 https://doi.org/10.1111/apt.12090
  73. Moore AR, Boyce M, Steele IA, Campbell F, Varro A, Pritchard DM. Netazepide, a gastrin receptor antagonist, normalises tumour biomarkers and causes regression of type 1 gastric neuroendocrine tumours in a nonrandomised trial of patients with chronic atrophic gastritis. PLoS One. 2013;8:e76462. PMID: 24098507 https://doi.org/10.1371/journal.pone.0076462
  74. Norton JA, Alexander HR, Fraker DL, Venzon DJ, Gibril F, Jensen RT. Does the use of routine duodenotomy (DUODX) affect rate of cure, development of liver metastases, or survival in patients with Zollinger-Ellison syndrome? Ann Surg. 2004;239:617-625; discussion 626. PMID: 15082965 https://doi.org/10.1097/01.sla.0000124290.05524.5e
  75. Norton JA, Jensen RT. Resolved and unresolved controversies in the surgical management of patients with Zollinger-Ellison syndrome. Ann Surg. 2004;240:757-773. PMID: 15492556 https://doi.org/10.1097/01.sla.0000143252.02142.3e
  76. La Rosa S, Vanoli A. Gastric neuroendocrine neoplasms and related precursor lesions. J Clin Pathol. 2014;67:938-948. PMID: 25053544 https://doi.org/10.1136/jclinpath-2014-202515
  77. Ramage JK, Ahmed A, Ardill J, Bax N, Breen DJ, Caplin ME, Corrie P, Davar J, Davies AH, Lewington V, Meyer T, Newell-Price J, Poston G, Reed N, Rockall A, Steward W, Thakker RV, Toubanakis C, Valle J, Verbeke C, Grossman AB. Guidelines for the management of gastroenteropancreatic neuroendocrine (including carcinoid) tumours (NETs). Gut. 2012;61:6-32.
  78. Kwon YH, Jeon SW, Kim GH, Kim JI, Chung IK, Jee SR, Kim HU, Seo GS, Baik GH, Choi KD, Moon JS. Long-term follow up of endoscopic resection for type 3 gastric NET. World J Gastroenterol. 2013;19:8703-8708. PMID: 24379589 https://doi.org/10.3748/wjg.v19.i46.8703
  79. Khuroo MS, Khuroo NS. Treatment of type I gastric neuroendocrine tumors with somatostatin analogs. J Gastroenterol Hepatol. 2010;25:548-554.
  80. Touzios JG, Kiely JM, Pitt SC, Rilling WS, Quebbeman EJ, Wilson SD, Pitt HA. Neuroendocrine hepatic metastases: does aggressive management improve survival? Ann Surg. 2005;241:776-783.
  81. Gunji N, Miyamoto H, Orii K, Kawamoto T, Fukao K. Pancreatic carcinoid: transcatheter arterial chemoembolization of liver metastases. Hepatogastroenterology. 2003;50:2166-2168.
  82. Oberg K, Jelic S. Neuroendocrine gastroenteropancreatic tumors: ESMO clinical recommendations for diagnosis, treatment and follow-up. Ann Oncol. 2008;19(Suppl 2):l04-l05.
  83. Oberg K. Chemotherapy and biotherapy in the treatment of neuroendocrine tumours. Ann Oncol. 2001;12(Suppl 2):111-114.
  84. Yao JC, Shah MH, Ito T, Bohas CL, Wolin EM, Van Cutsem E, Hobday TJ, Okusaka T, Capdevila J, de Vries EGE, Tomassetti P, Pavel ME, Hoosen S, Haas T, Lincy J, Lebwohl D, Oberg K. Everolimus for advanced pancreatic neuroendocrine tumors. N Engl J Med. 2011;364:514-523.
  85. Kwekkeboom DJ, de Herder WW, Kam BL, van Eijck CH, van Essen M, Kooij PP, Feelders RA, van Aken MO, Krenning EP. Treatment with the radiolabeled somatostatin analog [177Lu-DOTA, Tyr3] octreotate: toxicity, efficacy, and survival. J Clin Oncol. 2008;26:2124-2130.
  86. Fendrich V, Waldmann J, Bartsch DK, Langer P. Surgical management of pancreatic endocrine tumors. Nat Rev Clin Oncol. 2009;6:419-428.

Close metadata

Contact the author
Email
Message
The publishing house "Media Sphere" does not provide treatment services, does not give recommendations on contacting medical institutions and specific specialists, on the prescription of medicines and dietary supplements.

Email Confirmation

An email was sent to test@gmail.com with a confirmation link. Follow the link from the letter to complete the registration on the site.

Email Confirmation

Contact us
If you have any questions, complaints or suggestions, please use this feedback form.
Email
Message
The publishing house "Media Sphere" does not provide treatment services, does not give recommendations on contacting medical institutions and specific specialists, on the prescription of medicines and dietary supplements.
Submit Application

You can become an author of one of our magazines, send a request and we will consider it in during the day.

Name
Phone
E-mail
Message
Login
Registration
E-mail
Password
Forgot Password?

Log in to the site using your account in one of the services

Password recovery
E-mail
Login
Register


We use cооkies to improve the performance of the site. By staying on our site, you agree to the terms of use of cооkies. To view our Privacy and Cookie Policy, please. click here.